Becton Dickinson price target lowered to $175 from $195 at RBC Capital

RBC Capital lowered the firm’s price target on Becton Dickinson (BDX) to $175 from $195 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q1 results for MedTech names. The firm notes that its intra-quarter due diligence suggests strong fundamentals and stable end markets, with no demand disruption in sight. RBC also believes that the current sentiment-driven dislocation is unwarranted, creating attractive opportunities across the landscape both into Q1 earnings season and longer-term. For the company, however, the firm believes that the stock may be range-bound as it lacks a meaningful catalyst and Alaris remains a headwind in FY26 and FY27.